Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences, Inc. announced the U.S. FDA approval of INGREZZA SPRINKLE (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. This new oral granules formulation provides an alternative administration option for patients with swallowing difficulties. INGREZZA SPRINKLE offers three effective dosages and can be easily sprinkled on soft food for oral administration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.